Arvinas Inc (ARVN) Stock Price, Quote & News

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 535 1456

Website: www.arvinas.com

Address:

5 Science Park, 395 Winchester Avenue, New Haven, United States

Stockwatcher9999 Dec. 20 at 10:48 PM

$ARVN -im long here but i am a little confused why neither arvinas or $PFE wants to commercialize vepdeg. I totally get why arvinas doesnt want too but curious if i missed anything here.

1 · Reply

erpy Dec. 20 at 9:14 PM

$ARVN Ive been adding ! Think it moves higher soon. Jmho

0 · Reply

Greatguns Dec. 18 at 10:50 PM

$ARVN Is ARVN ready to move higher? 1,2,3 Pullback Bullish shows up after slipping 1.51%

0 · Reply

Regulator06 Dec. 18 at 11:58 AM

$ARVN Great games tonight (Rams at Seahawks) and tomorrow night (Bama at Sooners). I will take Seahawks -1 and Bama -1. Profits will go straight to this.

0 · Reply

NewGuyHere94 Dec. 17 at 9:45 PM

$ARVN the drop before the storm?

0 · Reply

Regulator06 Dec. 17 at 6:34 PM

$ARVN This is the shakedown and management already knew, imo, and prepared with their $100M in reserve for the buy back. Opportunity to load here before the mega rise. Good luck!

1 · Reply

JarvisFlow Dec. 17 at 5:46 PM

Barclays updates rating for Arvinas ( $ARVN ) to Overweight, target set at 16 → 18.

0 · Reply

Stockwatcher9999 Dec. 13 at 4:05 PM

$ARVN - movement/news is needed on vepdeg clarity for the third party doing the commercialization.

0 · Reply

outlawinvestor1 Dec. 12 at 7:56 PM

$ARVN vepdeg still looks decent. perhaps, $RHHBY should dump their combo w/ giredestrant approach and buy vepdeg, although $OLMA may also be a worthwhile investment for them, if ph3 is successful.

0 · Reply

NewGuyHere94 Dec. 11 at 9:44 PM

$ARVN another presentation tomorrow morning, may see some movement

1 · Reply

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Nov 26, 2025, 7:00 AM EST - 4 weeks ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Nov 5, 2025, 3:01 PM EST - 7 weeks ago

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 3, 2025, 4:00 PM EST - 7 weeks ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 7:00 AM EST - 7 weeks ago

Arvinas to Participate in Upcoming Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 2 months ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 24, 2025, 4:00 PM EDT - 2 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 2 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 20, 2025, 4:15 AM EDT - 2 months ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Oct 13, 2025, 7:00 AM EDT - 2 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 5, 2025, 2:00 PM EDT - 2 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 3 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Sep 17, 2025, 5:50 PM EDT - 3 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Sep 17, 2025, 4:30 PM EDT - 3 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 9, 2025, 10:12 AM EDT - 3 months ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 8, 2025, 4:05 PM EDT - 4 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 6, 2025, 1:24 PM EDT - 5 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 5 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 4:05 PM EDT - 5 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 9, 2025, 7:00 AM EDT - 6 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jun 13, 2025, 7:00 AM EDT - 6 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 6, 2025, 7:00 AM EDT - 7 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 5, 2025, 8:28 AM EDT - 7 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

May 31, 2025, 8:06 AM EDT - 7 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

May 31, 2025, 8:00 AM EDT - 7 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 30, 2025, 7:00 AM EDT - 7 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

May 16, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 14, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 8 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 9, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 8, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 7, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

Stockwatcher9999 Dec. 20 at 10:48 PM

$ARVN -im long here but i am a little confused why neither arvinas or $PFE wants to commercialize vepdeg. I totally get why arvinas doesnt want too but curious if i missed anything here.

1 · Reply

erpy Dec. 20 at 9:14 PM

$ARVN Ive been adding ! Think it moves higher soon. Jmho

0 · Reply

Greatguns Dec. 18 at 10:50 PM

$ARVN Is ARVN ready to move higher? 1,2,3 Pullback Bullish shows up after slipping 1.51%

0 · Reply

Regulator06 Dec. 18 at 11:58 AM

$ARVN Great games tonight (Rams at Seahawks) and tomorrow night (Bama at Sooners). I will take Seahawks -1 and Bama -1. Profits will go straight to this.

0 · Reply

NewGuyHere94 Dec. 17 at 9:45 PM

$ARVN the drop before the storm?

0 · Reply

Regulator06 Dec. 17 at 6:34 PM

$ARVN This is the shakedown and management already knew, imo, and prepared with their $100M in reserve for the buy back. Opportunity to load here before the mega rise. Good luck!

1 · Reply

JarvisFlow Dec. 17 at 5:46 PM

Barclays updates rating for Arvinas ( $ARVN ) to Overweight, target set at 16 → 18.

0 · Reply

Stockwatcher9999 Dec. 13 at 4:05 PM

$ARVN - movement/news is needed on vepdeg clarity for the third party doing the commercialization.

0 · Reply

outlawinvestor1 Dec. 12 at 7:56 PM

$ARVN vepdeg still looks decent. perhaps, $RHHBY should dump their combo w/ giredestrant approach and buy vepdeg, although $OLMA may also be a worthwhile investment for them, if ph3 is successful.

0 · Reply

NewGuyHere94 Dec. 11 at 9:44 PM

$ARVN another presentation tomorrow morning, may see some movement

1 · Reply

DanishViking92 Dec. 10 at 1:20 PM

$ARVN

0 · Reply

McMillion1 Dec. 10 at 12:38 PM

$IOVA $ARVN within 6 months 🚀

0 · Reply

Regulator06 Dec. 10 at 12:18 PM

$ARVN Great company here just accumulate and hold. They have $100M designated for buy back in case it falls big time. Their debt is $400K and their cash is over$600M. Multiple verticals, imo, at least 2 will be FDA approved.

1 · Reply

RocketshipCalls Dec. 10 at 5:14 AM

$SAVA insiders buying more. Last time we saw a spike in insider buying we jumped a huge amount! Do some DD here. The CEO keeps buying thousands! I see a big news drop coming and a multi bagger here $ARVN $MIST $SPY $CTHZ

0 · Reply

DanishViking92 Dec. 9 at 6:06 PM

$ARVN

1 · Reply

DanishViking92 Dec. 9 at 6:04 PM

$ARVN my bad phase 3 is old news.. but maybe we get some status update. But ai also says we are going to see data from a Phase 1/2 study regarding circulating tumor DNA biomarker analyses for their drug candidate, vepdegestrant (ARV-471). Can anyone confirm that they actually are going to present these 1/2 clinical data tomorrow?

1 · Reply

DanishViking92 Dec. 9 at 5:33 PM

$ARVN isnt ai amazing? feeling stupid that i was locked on the pre clinical data last weekend, the news that make this move is those tomorrow!

0 · Reply

DanishViking92 Dec. 9 at 4:38 PM

$ARVN buy ffs buy!!

0 · Reply

DanishViking92 Dec. 9 at 4:32 PM

$ARVN Must admit i was too fast selling this.. i expect some news tomorrows from that cancer presentation (maybe about Pfizer partnership!) this stock screams +$17 this month and insiders bought big aswell. The pre clinical data wasnt the key to bigger movements here, but tomorrow could very likely be the day they announce the news we need to get this moving! $$ only holding for tomorrow because i need to be in $MIST for approval.. running a big risk here gambling on this one to move tomorrow and that mist isnt going to announce FDA approval tomorrow. But im willing to take that risk, because this chart is so overwhelming positive/bullish!

2 · Reply

CaptainCihan Dec. 9 at 12:09 PM

$ARVN “Rather than investing in ARVN, I see ASBP as a far more reliable opportunity. They’re formulating therapies that are already validated, which significantly reduces the risk. On top of that, ASBP appears to offer stronger market potential and a much shorter path to meaningful returns. Just my perspective, but the upside here looks far more compelling.”

0 · Reply

cheruskian Dec. 9 at 9:14 AM

$KYMR it's like no one remembers when $ARVN kissed the $100 based on an over hyped phase 1 data.

1 · Reply

FishinwithJesus Dec. 8 at 8:31 PM

$ARVN I love that no one is talking about it! Get more early before they arrive!

0 · Reply

Market Cap	782.25M
Revenue (ttm)	263.40M
Net Income (ttm)	-198.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-75.51%
Debt to Equity Ratio	0.00

Volume	370,600
Avg Vol	2,128,604
Day's Range	N/A - N/A
Shares Out	64.22M
Stochastic %K	57%
Beta	2.44
Analysts	Sell
Price Target	$12.44